HomePSTV • NASDAQ
add
Plus Therapeutics Inc
Previous close
$0.47
Day range
$0.44 - $0.47
Year range
$0.16 - $2.31
Market cap
44.39M USD
Avg Volume
11.58M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Market news
Financials
Income Statement
Revenue
Net income
| (USD) | Jun 2025info | Y/Y change |
|---|---|---|
Revenue | 1.39M | 8.68% |
Operating expense | 1.68M | -23.65% |
Net income | 5.15M | 275.20% |
Net profit margin | 370.58 | 261.21% |
Earnings per share | -0.01 | 98.56% |
EBITDA | -1.46M | 58.58% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Jun 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 6.88M | -18.45% |
Total assets | 10.35M | -7.69% |
Total liabilities | 7.32M | -61.16% |
Total equity | 3.03M | — |
Shares outstanding | 99.26M | — |
Price to book | 15.66 | — |
Return on assets | -34.32% | — |
Return on capital | 37.44% | — |
Cash Flow
Net change in cash
| (USD) | Jun 2025info | Y/Y change |
|---|---|---|
Net income | 5.15M | 275.20% |
Cash from operations | -5.80M | -404.17% |
Cash from investing | -4.63M | -21.83% |
Cash from financing | 2.80M | -59.84% |
Net change in cash | -7.63M | -479.61% |
Free cash flow | -5.31M | -186.64% |
About
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company headquartered in Houston, Texas, that develops targeted radiotherapeutics and diagnostic services for brain and central nervous system cancers. The company’s lead therapeutic candidate, marketed as REYOBIQ™, is an investigational liposomal radiopharmaceutical under clinical evaluation for recurrent glioblastoma, leptomeningeal metastases, and certain pediatric brain cancers. Plus Therapeutics also commercialized a molecular diagnostic service, CNSide®. Wikipedia
Founded
1996
Headquarters
Website
Employees
21
